Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
Lisbon, Portugal (ots/PRNewswire) - Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1] According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European ...
Lisbon, Portugal (ots/PRNewswire) - Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included ...
Lisbon, Portugal (ots/PRNewswire) - Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings[4]. (Logo: ...
Teva Pharmaceuticals Europe BV
Amsterdam (ots/PRNewswire) - ONLY FOR PAN-EUROPEAN/ EUROPEAN ENGLISH LANGUAGE MEDICAL TRADE MEDIA Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax® Teva Pharmaceuticals Europe B.V., (NYSE and TASE: TEVA) today announced data from ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on areas of high unmet need to help enhance ...
Cambridge, England (ots/PRNewswire) - - First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients - Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New ...
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...
Cork, Ireland (ots/PRNewswire) - - Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK/U.S. based media - EUR1 million grant funded by Merck supports research with the potential to advance implementation of personalized treatment for solid tumors - Three winners selected from 100 scientifically diverse applicants worldwide Merck, a leading ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices - Pharmacokinetic ...
Beerse, Belgium (ots/PRNewswire) - Janssen announces results of pan-European research which shows that a third of psychiatrists (34%) delay conversations about the full range of treatment options with their patients living with schizophrenia. The 'Open Minds' survey, conducted among 347 psychiatrists across eight ...
Tokyo and Cambridge, England (ots/PRNewswire) - SciBite - The award-winning semantic analytics company, today announced that GlaxoSmithKline K.K. (hereinafter referred to as GSK Japan), one of Japan's leading research-based pharmaceutical and healthcare companies, has selected SciBite's Semantic Platform to enhance ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. or U.S. based media ESMO 2017 abstract # Erbitux®: 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib (c-Met kinase inhibitor): 701P - Data to showcase Merck's strong and diverse pipeline ranging from ...
Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular ...
Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...
Barcelona, Spain (ots/PRNewswire) - Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not ...
Amsterdam and Redwood City, California (ots/PRNewswire) - Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care Royal Philips (http://www.usa.philips.com/) (NYSE: PHG, AEX: PHIA) and HeartFlow, Inc. (http://www.heartflow.com/) announced today that they have entered into a collaboration agreement with the goal of improving access to diagnostic and ...
Darmstadt, Germany (ots/PRNewswire) - - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe - MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Marketing authorization includes the 28 countries of the European Union (EU), with first ...
Amsterdam and Barcelona, Spain (ots/PRNewswire) - - Spotlights patient-centric cardiovascular solutions for diagnosis, image-guided therapy and connected care through patient monitoring - Demonstrates Philips' commitment to delivering seamless care Royal Philips (http://www.philips.com/digitalpathology) (NYSE: PHG, ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Decision secures access to Erbitux® for new patients in England with oral cavity tumors - All patients currently receiving Erbitux® will have continued access Merck, a leading science and technology company, announced today that the ...
Ballerup, Denmark and Hurley, England (ots/PRNewswire) - New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO Pharma is ranked at number ...
London (ots/PRNewswire) - DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING. This is a ...
Calgary, Alberta (ots/PRNewswire) - "BETonMACE Phase 3 Trial with apabetalone to expand to include the United States" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the receipt of a positive Type C written response from the Division of Metabolism and Endocrinology Products of the ...
Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ...
Sunnyvale, California (ots/PRNewswire) - Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function Accuray Incorporated ...
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.[1] ...